Multidisciplinary consensus on the combined management of Alzheimer's disease by Mexican experts: recommendations and guidelines.

Objective: Alzheimer's disease (AD), affecting over 55 million people globally, poses a substantial public health challenge. Early diagnosis and appropriate treatment are vital to slowing its progression and enhancing patient quality of life. The fixed-dose combination of citicoline with rivastigmine emerges as a promising strategy AD treatment. Methods: A real-time Delphi consensus was reached with the participation of 11 Mexican experts. Results: The combination offers neuroprotective benefits, enhancing neuronal regeneration and reducing glutamate levels linked to neuronal damage in AD. These effects translate into improved cognitive function and delayed cognitive decline in AD. Conclusions: The Mexican Consensus for the Combined Management of AD endorses this fixed-dose combination of rivastigmine with citicoline as a new therapeutic perspective. Its efficacy and safety make it a valuable option for the treatment of this neurodegenerative disease. [ABSTRACT FROM AUTHOR]